Published in Clin Infect Dis on March 01, 2010
COMO: Cognition Study With HIV+ Patients (CTNPT 015) (COMO) | NCT02144688
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis (2012) 2.37
HIV-associated neurocognitive disorder. Lancet Infect Dis (2013) 1.60
The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis (2011) 1.54
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One (2011) 1.38
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine (2015) 1.36
HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med (2012) 1.34
Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev (2013) 1.31
Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis (2012) 1.31
Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep (2011) 1.26
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
HIV reservoirs: what, where and how to target them. Nat Rev Microbiol (2015) 1.13
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One (2014) 1.12
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. J Neurovirol (2016) 1.08
Controversies in HIV-associated neurocognitive disorders. Lancet Neurol (2014) 1.07
Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ-opioid receptor-expressing glia. Brain (2011) 1.06
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis (2013) 1.05
Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? BMC Med (2011) 1.05
Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep (2015) 1.03
Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol (2013) 0.98
Neuropathogenesis of HIV-associated neurocognitive disorders: roles for immune activation, HIV blipping and viral tropism. Curr Opin HIV AIDS (2014) 0.97
How much do antiretroviral drugs penetrate into the central nervous system? J Med Life (2011) 0.91
Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistence. Curr HIV/AIDS Rep (2014) 0.91
HIV and neurocognitive dysfunction. Curr HIV/AIDS Rep (2013) 0.91
Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One (2013) 0.91
Cerebrospinal fluid HIV-1 compartmentalization in a patient with AIDS and acute varicella-zoster virus meningomyeloradiculitis. Clin Infect Dis (2013) 0.90
Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy. Scand J Infect Dis (2012) 0.89
Evolving character of chronic central nervous system HIV infection. Semin Neurol (2014) 0.89
The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics (2012) 0.88
Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. J Neurol (2015) 0.88
Recent developments in human immunodeficiency virus-1 latency research. J Gen Virol (2013) 0.87
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations. J Clin Pharmacol (2014) 0.85
Tissue reservoirs of HIV. Curr Opin HIV AIDS (2016) 0.83
CNS reservoirs for HIV: implications for eradication. J Virus Erad (2015) 0.83
Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. AIDS (2015) 0.83
CCR5 blockade for neuroinflammatory diseases - beyond control of HIV. Nat Rev Neurol (2016) 0.83
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis (2014) 0.82
Immune activation in the central nervous system throughout the course of HIV infection. Curr Opin HIV AIDS (2016) 0.82
Leukotrienes inhibit early stages of HIV-1 infection in monocyte-derived microglia-like cells. J Neuroinflammation (2012) 0.82
HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy. Med Microbiol Immunol (2016) 0.81
CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. Cytokine (2016) 0.80
The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review. CNS Drugs (2016) 0.80
The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease. AIDS Res Ther (2015) 0.79
The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV. Am J Epidemiol (2014) 0.79
Enhanced antagonism of BST-2 by a neurovirulent SIV envelope. J Clin Invest (2016) 0.79
Viral escape in the CNS with multidrug-resistant HIV-1. J Int AIDS Soc (2014) 0.78
Cerebrospinal fluid can be used for HIV genotyping when it fails in blood. Arq Neuropsiquiatr (2014) 0.78
Hepatitis B virus compartmentalization in the cerebrospinal fluid of HIV-infected patients. Clin Microbiol Infect (2014) 0.78
Interactions between prostaglandins, leukotrienes and HIV-1: possible implications for the central nervous system. Retrovirology (2012) 0.77
Early detection of simian immunodeficiency virus in the central nervous system following oral administration to rhesus macaques. Front Immunol (2013) 0.77
HIV-associated neurocognitive disorders: perspective on management strategies. Drugs (2013) 0.77
Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions. Drugs (2015) 0.77
Deep sequencing of HIV-1 variants from paired plasma and cerebrospinal fluid during primary HIV infection. J Virus Erad (2016) 0.76
Cognitive Impairment and Persistent CNS Injury in Treated HIV. Curr HIV/AIDS Rep (2016) 0.76
Update and New Directions in Therapeutics for Neurological Complications of HIV Infections. Neurotherapeutics (2016) 0.75
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. Medicine (Baltimore) (2016) 0.75
HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. F1000Res (2017) 0.75
Targeting the Brain Reservoirs: Toward an HIV Cure. Front Immunol (2016) 0.75
Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic. PLoS One (2016) 0.75
HIV cure strategists: ignore the central nervous system at your patients' peril. AIDS (2017) 0.75
Fate of microglia during HIV-1 infection: From activation to senescence? Glia (2016) 0.75
Perinatally HIV-infected youth presenting with acute stroke: progression/evolution of ischemic disease on neuroimaging. J Neuroradiol (2013) 0.75
A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. EMBO J (2017) 0.75
Classification models for neurocognitive impairment in HIV infection based on demographic and clinical variables. PLoS One (2014) 0.75
Viral Escape in the Central Nervous System with Multidrug-Resistant Human Immunodeficiency Virus-1. Open Forum Infect Dis (2015) 0.75
Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. AIDS Res Treat (2012) 0.75
Impact of antiretroviral therapy on HIV-related brain injury. Clin Infect Dis (2011) 0.75
Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis (2016) 0.75
A comparative study of CIDP in a cohort of HIV-infected and HIV-uninfected patients. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
Relationship of Human Immunodeficiency Virus Viral Load in Cerebrospinal Fluid and Plasma in Patients Co-infected With Cryptococcal Meningitis. Open Forum Infect Dis (2017) 0.75
Relevance of retrovirus quantification in cerebrospinal fluid for neurologic diagnosis. J Biomed Sci (2015) 0.75
Neurocognition with maraviroc compared with tenofovir in HIV. AIDS (2016) 0.75
Dynamic of CSF and serum biomarkers in HIV-1 subtype C encephalitis with CNS genetic compartmentalization-case study. J Neurovirol (2017) 0.75
Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. J Virus Erad (2016) 0.75
HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol (2017) 0.75
Evaluation of the Aptima HIV-1 Quant Dx Assay for HIV-1 RNA Quantitation in Different Biological Specimen Types. J Clin Microbiol (2017) 0.75
Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms. Clin Infect Dis (2017) 0.75
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet (2004) 4.81
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. Clin Infect Dis (2003) 2.33
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS (2008) 2.27
Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS (2008) 2.19
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. AIDS (2007) 2.17
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis (2006) 2.08
Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. Ann Intern Med (2002) 2.05
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (2002) 2.03
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS (2014) 2.02
Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis (2011) 2.01
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS (2003) 1.97
Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS (2003) 1.94
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis (2012) 1.80
Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys. PLoS Med (2013) 1.78
Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS (2006) 1.76
Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS (2009) 1.74
Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med (2009) 1.73
Chikungunya infection in travelers. Emerg Infect Dis (2006) 1.70
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. AIDS (2010) 1.65
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS (2003) 1.64
CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis (2013) 1.60
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother (2009) 1.59
Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP study. PLoS One (2012) 1.56
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS (2006) 1.52
Splenic infarction during acute malaria. Trans R Soc Trop Med Hyg (2005) 1.51
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol (2006) 1.51
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol (2007) 1.48
Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS (2011) 1.47
Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study. J Acquir Immune Defic Syndr (2008) 1.46
Chagas disease: changes in knowledge and management. Lancet Infect Dis (2010) 1.46
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS (2005) 1.45
The marriage of science and optimized HIV care in resource-limited settings. AIDS (2008) 1.44
Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.44
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS (2004) 1.44
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr (2003) 1.44
Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med (2005) 1.43
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS (2003) 1.43
Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol (2005) 1.43
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic Clin Pharmacol Toxicol (2011) 1.42
Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS (2004) 1.42
Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV. AIDS (2005) 1.40
[Kidney and HIV infection]. Presse Med (2012) 1.39
Limb swelling with hypereosinophilia. Lancet (2006) 1.38
Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis (2011) 1.37
Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS (2012) 1.36
Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS (2002) 1.35
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35
Virological rebound after suppression on highly active antiretroviral therapy. AIDS (2003) 1.34
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother (2003) 1.31
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother (2007) 1.30
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother (2008) 1.30
AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol (2008) 1.28
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology (2006) 1.28
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS (2006) 1.28
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg (2010) 1.28